Biogen Idec Issues Statement on U.S. Approval of AMPYRA™
News Jan 25, 2010
Biogen Idec has issued the following statement regarding the United States (U.S.) Food and Drug Administration (FDA) approval of AMPYRA™ (dalfampridine) to improve walking in patients with multiple sclerosis (MS). This was demonstrated by an increase in walking speed. The U.S. FDA approval was granted on January 22, 2010.
AMPYRA will be marketed in the U.S by Acorda Therapeutics, Inc. AMPYRA is an extended release tablet formulation of the investigational drug dalfampridine. Biogen Idec will commercialize fampridine as a prolonged release tablet in markets outside of the U.S.
“For people with MS, impaired walking ability is one of the most common and concerning aspects of the disease,” said Alfred Sandrock, MD, PhD, senior vice president, Neurology Research and Development, Biogen Idec. “AMPYRA may be an important therapy in reducing the impact of this debilitating condition.”
“We congratulate our partner, Acorda Therapeutics, on this important achievement and look forward to working with regulators outside of the U.S. to make this therapy available to all people living with MS.”
On 12 January 2010, Biogen Idec announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency for prolonged release fampridine tablets for the improvement of walking ability in adult patients with multiple sclerosis (MS). The company also has filed a New Drug Submission (NDS) to Health Canada.
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE